Auro-Emtricitabine Tenofovir is indicated in combination with safer sex practices for PrEP to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.
Follow the links below to get educational material for prescribers and health professionals about Auro Emtricitabine Tenofovir. This material was developed by Auro Pharma, as part of the Fisk minimization plan for Auro- Emtricitabine Tenofovir. This material is not intended for promotional use.
Product Monograph
Download Product Monograph to obtain important information
Additional Information:
Please contact our Medical Information Services for additional information about this product or to report an adverse event.
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways: by calling toll-free at 1-866-234 2345, online at www.healthcanada.gc.ca/medeffect or by completing a Canada Vigilance Reporting Form which you can send by fax toll-free to 1-866-678-6789
You can also report an adverse event to Pharmacovigilance Team at Auro Pharma, Inc. by calling 1 855-648 6681 or by e-mailing pvteam@auropharma.ca.
Seroconversion while on Aum-Emtricitabine-Tenofovir for PrEP is considered an adverte ever and hould be reported.
ᴾʳAuro-Emtricitabine -Tenofovir
(200 mg/300 mg)
Important Notice
If you are HIV-positive, PRAuro-Emtricitabine-Tenofovir should only be combined with other antiretroviral agents. For more information, please consult your healthcare professional. For Pre-Exposure Prophylaxis, PrAuro-Emtricitabine-lenotovir is indicated in combination with safer sex practices for PrEP to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. This material was developed by Auro Pharma, as part of the risk minimization plan for PrAuro-Emtricitabine-Tenofovir. This material is not intended for promotional use.
Follow the links below to get more information about PrAuro-Emtricitabine-Tenofovir:
- Pre-Exposure Prophylaxis patient brochure
- Consumer information
Additional Information:
The information above does not constitute medical advice. Consult your doctor or pharmacist for more information about the product or possible side effects.
You can report any suspected adverse reactions associated with the
use of health products (becoming HIV-1 positive while on Auro-Emtricitabine-tenofovir for PrEP is considered an adverse event) to the Canadian Vigilance Program at 1-866-234-2345 or online at www.healthcanada.gc.ca/medeffect
Follow Us:
Customer Support
Phone: +1-905-856-8063
Email: cs@auropharma.ca
Follow Us:
Medical information
Phone: +1-855-648-6681
Email: pvteam@auropharma.ca
